Hudson Valley Investment Advisors Inc. ADV Cuts Holdings in Pfizer Inc. (NYSE:PFE)

Hudson Valley Investment Advisors Inc. ADV trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 76.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,392 shares of the biopharmaceutical company’s stock after selling 119,705 shares during the period. Hudson Valley Investment Advisors Inc. ADV’s holdings in Pfizer were worth $922,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Impact Capital Partners LLC raised its stake in shares of Pfizer by 26.5% during the 1st quarter. Impact Capital Partners LLC now owns 13,686 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 2,864 shares in the last quarter. Pitti Group Wealth Management LLC raised its stake in shares of Pfizer by 7.5% during the 1st quarter. Pitti Group Wealth Management LLC now owns 15,186 shares of the biopharmaceutical company’s stock worth $385,000 after buying an additional 1,060 shares in the last quarter. SeaCrest Wealth Management LLC raised its stake in shares of Pfizer by 4.2% during the 1st quarter. SeaCrest Wealth Management LLC now owns 68,330 shares of the biopharmaceutical company’s stock worth $1,731,000 after buying an additional 2,740 shares in the last quarter. Procyon Advisors LLC raised its stake in shares of Pfizer by 41.4% during the 1st quarter. Procyon Advisors LLC now owns 78,591 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 23,020 shares in the last quarter. Finally, Next Level Private LLC raised its stake in shares of Pfizer by 31.3% during the 1st quarter. Next Level Private LLC now owns 56,877 shares of the biopharmaceutical company’s stock worth $1,441,000 after buying an additional 13,543 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $23.36 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a fifty day moving average of $22.95 and a two-hundred day moving average of $25.00. The company has a market capitalization of $132.81 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.82 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.